Vor bio announces $55.6 million private placement

Intend to announce updated clinical data from phase 1/2 vbp301 trial of vcar33 allo in the first half of 2025 and updated clinical data from phase 1/2a vbp101 trial of trem-cel in combination with mylotarg in the second half of 2025

VOR Ratings Summary

VOR Quant Ranking